<DOC>
	<DOCNO>NCT00812812</DOCNO>
	<brief_summary>This study design compare efficacy oral paroxetine 10 40 mg/day ( initial dose:10 mg/day ) versus placebo administer daily ( even meal ) 8 week child adolescent major depressive disorder ( MDD ) base change baseline Week 8/end-of-study CDRS-R total score randomize , double-blind , placebo-controlled parallel-group study .</brief_summary>
	<brief_title>Paxil Japanese Post Marketing Paediatric Study Depression ( Double-blind , Placebo Controlled Study )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>runin period : A subject consider eligible study follow criterion apply start placebo runin period . Patients diagnose follow depressive disorder accord DSMIVTR criterion , currently present depressive episode . Depressive disorder : MDD , single episode ( 296.2 ) , MDD , recurrent ( 296.3 ) 7 year old 18 year old ( time consent obtain ) Patients total raw summary score CDRSR 45 great Week 2 visit . Patients whose legally acceptable representative ( e.g. , caretaker , custodian ) able give write consent participation study . Patients age 12 time consent obtain able sign inform consent one 's . Efforts exert obtain informed assent write patient age less 12 . Patients ideal body weight +/ 2SD Gender : Male female treatment period : Subjects meet follow criterion Week 0 ( Baseline ) may progress Treatment period : Patients total raw summary score CDRSR Week 0 visit 45 great . Exclusion Criteria runin period : A subject eligible inclusion study follow criterion applies start runin period : Patients investigator 's judgment present clinically predominant Axis I disorder MDD ( e.g . dysthymic disorder , eat disorder , Specific phobia , PTSD , OCD , Panic disorder , etc ) Patients history psychotic episode psychotic disorder ( include schizophrenia ) , complication disease . Patients history bipolar disorder , complication disease . Patients AttentionDeficit , Hyperactivity Disorder Patients Mental Retardation Pervasive Development Disorder Patients diagnose Substance Abuse Dependence within 12 week prior Screening visit Patients past treatment experience investigational drug ( i.e . paroxetine ) Patients treat electroconvulsive therapy immediate 12 week prior Screening visit Patients past history serotonin syndrome neuroleptic malignant syndrome . Patients CDRSR score `` suicidal ideation '' 3 great . Or patient whose CSSRS assessment suggest significant risk harm actually harm , , opinion chief investigator ( subinvestigator ) , significant risk harm self . Patients past history suicide attempt , self harm ( exclude `` suicidal intent `` ) , intentional overdose ( exclude obviously unintentional overdose ) Patients treat clinical trial investigational drug ( include postmarketing clinical trial ) immediate past 3 month Week 2 visit . Patients take antidepressant medication 1 week prior screen . Patients complicate disease glaucoma . Patients convulsive disorder epilepsy past history disease . Patients regularly use drug ( e.g . NSAIDs ) would increase risk haemorrhage , patient bleed tendency haemorrhagic diathesis . Patients severe renal hepatic disorder . Patients serious organic disorder brain . Patients chronic hepatitis type B and/or C positive hepatitis B surface antigen ( HBsAg ) and/or hepatitis C antibody . Patients current history carcinoma malignant tumor , complication disease . Female patient pregnant , lactate , might pregnant , wish pregnant study period Patients opinion chief investigator ( subinvestigator ) judge eligible study . Patients clinical significant comorbid impulsivity symptoms. ( e.g . Personality Disorder , Conduct Disorder ) treatment period : Subjects follow category apply Week 0 ( start treatment period ) progress treatment phase . Patients CDRSR score `` suicidal ideation '' 3 great , patient , opinion chief investigator ( sub investigator ) , significant risk harm self Patients variation CDRSR total raw summary score Week 0 +/25 % great compare Week 2 . Patients drug compliance Drug 1 ( runin placebo ) Week 2 Week 0 less 80 % . Patients , opinion chief investigator ( sub investigator ) judge appropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>paroxetine</keyword>
	<keyword>selective serotonin reuptake inhibitor</keyword>
	<keyword>CDRS-R</keyword>
	<keyword>child adolescent</keyword>
</DOC>